Mukesh Ambani, the chairman of Reliance Industries, renowned as one of India’s largest conglomerates, continues to broaden his empire. With his children, Akash, Anant, and Isha Ambani, strategically positioned within the group’s subsidiaries, Ambani oversees a vast network of enterprises.
As per Forbes, Ambani stands as the wealthiest individual in India and Asia, boasting a staggering real-time net worth of Rs 920,340 crore. His entrepreneurial vision has propelled Reliance Industries into various sectors, notably telecom and retail, solidifying its position as a powerhouse in the Indian market.
Now, Ambani, at 67, sets his sights on the lucrative USD 150 billion (Rs 1,252,740 crore) diagnostic healthcare segment. Reports from HinduBusinessline indicate that Reliance Retail Ventures, a subsidiary of the conglomerate, is gearing up to secure a controlling stake in a diagnostic services firm with investments ranging between Rs 1,000-3,000 crore.
Sources familiar with the matter reveal that Reliance aims to align with a nationwide player, emphasising the importance of a pan-India presence. Currently, Reliance Retail’s portfolio includes the online pharmacy giant, Netmeds, acquired in 2020 for Rs 620 crore. While Netmeds offers pathology services through collaborations with established names like Thyrocare and Healthians, Reliance envisions establishing its diagnostic arm with an extensive network of physical laboratories across the country.
Notably, Netmeds embarked on its offline expansion journey in January 2023, marking its presence with over 1000 outlets nationwide. With Ambani’s strategic foresight and Reliance’s formidable resources, the conglomerate’s foray into the diagnostic healthcare sector is poised to reshape the industry landscape, further solidifying its position as a key player in India’s evolving business ecosystem.
